Profile picture for Jack Cush, MD

Jack Cush, MD

Dr. Cush is the Executive Editor of RheumNow.com and also Co-Edits the online textbook RheumaKnowledgy.com. 
  
Dr. Cush's interests include medical education, novel drug development, rheumatoid arthritis, spondyloarthritis, drug safety, and Still's disease/autoinflammatory syndromes. He has published over 140 articles and 2 books in rheumatology.
 
He can be followed on twitter: @RheumNow

Articles By Jack Cush, MD

Level, monitor, calculate, glucose, diabetes

Metabolic Syndrome Predicts Cardiovascular Outcomes in Inflammatory Arthritis

By Jack Cush, MD

Chronic inflammatory arthritis (CIA) is associated with elevated cardiovascular risk. While metabolic syndrome (MetS) is prevalent, how much it contributes to adverse clinical outcomes is unclear.

Read Article
morbidity,covid,heart,lung,brain

More Comorbidity in Difficult to Treat RA

By Jack Cush, MD

A systematic review demonstrated that smoking, obesity, fibromyalgia, and depression are significantly associated with difficult-to-treat rheumatoid arthritis (D2T-RA).

Read Article
APR SLE VIDEO COVER

Systemic Lupus Erythematosus

By Jack Cush, MD

Dr. Cush reviews systemic lupus erythematosus.

Read Article
lectures

Great Lectures; Great Presentations

By Jack Cush, MD

Dr. Jack Cush lectures on giving a great presentation; based on 40 years of lecturing in Rheumatology.

Read Article
obesity.back_.jpg

Review of GLP-1 Receptor Agonists in Psoriasis

By Jack Cush, MD

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed cardiometabolic medicine and are now attracting intense interest in inflammatory disorders.

Read Article
Tavneos

FDA Targeting the Safety of Avacopan

By Jack Cush, MD

The future of avacopan is up in the air. In April, the FDA issued a drug safety warning, previously requesting that Amgen to pull its rare disease drug Tavneos from the market. Now, there appears more pressure to remove it from the market.

Read Article
exercise,group

EULAR Recommendations for Physical Activity in Arthritis

By Jack Cush, MD

EULAR has published a 2025 update for physical activity recommendations for patients with osteoarthritis (OA) and rheumatoid arthritis (RA). 

Read Article
STEROIDS COVER

Steroids

By Jack Cush, MD

In this Advanced Practice Rheum, Dr. Jack Cush reviews steroids.

Read Article
38420215_s.jpg

Neoplasia and Autoimmune Disease

By Jack Cush, MD

Malignancy rivals cardiovascular disease as a leading cause of death in patients with systemic autoimmune diseases. Chronic inflammation and immune dysregulation can drive oncogenesis, while antitumor immune responses can trigger autoimmune phenomena (paraneoplastic syndromes, checkpoint inhibitor-induced rheumatic disease).

Read Article
choices2.jpg

Switch or Cycle - Upadacitinib vs Adalimumab in Refractory RA

By Jack Cush, MD

After the first tumour necrosis factor inhibitor (TNFi) failure, patients with active rheumatoid arthritis (RA) responded by switching to upadacitinib, compared to cycling to a second TNFi, adalimumab.

Read Article
×